Company Overview of Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. is a stealth mode company which operates in biotech sector. Its products are products based on the science of nutrient sensing. The company was incorporated in 2009 and is based in San Diego, California.
11995 El Camino Real
San Diego, CA 92130
Founded in 2009
Key Executives for Elcelyx Therapeutics, Inc.
Executive Officer and Chairman
Executive Officer and Director
Senior Vice President of Business Development
Compensation as of Fiscal Year 2014.
Elcelyx Therapeutics, Inc. Key Developments
Elcelyx Therapeutics, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 10:55 AM
Oct 27 14
Elcelyx Therapeutics, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 10:55 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Mark C. Wiggins, Senior Vice President of Business Development.
Elcelyx Therapeutics, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 02:25 PM
Nov 15 13
Elcelyx Therapeutics, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 02:25 PM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States.
Elcelyx Therapeutics, Inc. Announces Positive Results in Phase 2B Study of NewMet in Type 2 Diabetes
Oct 21 13
Elcelyx Therapeutics, Inc. announced the completion of a 12-week Phase 2b study of NewMet(TM), a delayed-release formulation of metformin for the treatment of patients with Type 2 diabetes. Elcelyx previously reported that the study met its primary endpoint of statistically significant reduction in fasting plasma glucose at four weeks of treatment with NewMet compared to placebo. The 12-week data confirm the durability of the effect observed at four weeks. The randomized, 240-patient, multicenter, double-blind, dose-finding trial evaluated NewMet once-daily doses of 1000, 800 and 600 milligrams compared to placebo. There were also two unblinded reference arms with Glucophage(R) XR dosed once-daily at 1000 and 2000 milligrams. All NewMet arms showed efficacy comparable to or greater than 1000 milligrams of Glucophage XR. The NewMet 1000 milligram dose was approximately 50% more effective than 1000 milligrams of Glucophage XR and approximately 70% as effective as 2000 milligrams of Glucophage XR. A dose response trend was observed across the three NewMet doses, indicating higher doses of NewMet may provide greater efficacy. All doses of NewMet and Glucophage XR prevented the rise in HbA1c seen with placebo due to washout of previous anti-diabetic medications. All doses of NewMet and Glucophage XR were well tolerated and there were no meaningful weight changes observed. NewMet, which is targeted to the lower bowel, reduced systemic exposure by as much as 65% compared to metformin immediate release (IR) and metformin XR. The ability of NewMet to significantly reduce fasting plasma glucose over 12 weeks further confirms the durable efficacy of bowel-directed metformin. The dramatic reduction in plasma metformin exposure indicates that NewMet may be an appropriate treatment for Type 2 diabetes patients who have renal impairment and are contraindicated for metformin IR and metformin XR use due to the risk of lactic acidosis, a life-threatening condition that can result from metformin build-up in the blood.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|